CN102458441A - 用于治疗神经疾病的模型系统和治疗方案 - Google Patents

用于治疗神经疾病的模型系统和治疗方案 Download PDF

Info

Publication number
CN102458441A
CN102458441A CN2010800352462A CN201080035246A CN102458441A CN 102458441 A CN102458441 A CN 102458441A CN 2010800352462 A CN2010800352462 A CN 2010800352462A CN 201080035246 A CN201080035246 A CN 201080035246A CN 102458441 A CN102458441 A CN 102458441A
Authority
CN
China
Prior art keywords
medicament
peptide
blood vessel
experimenter
primate
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN2010800352462A
Other languages
English (en)
Chinese (zh)
Inventor
M·蒂米安斯基
J·D·加曼
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
NoNO Inc
Original Assignee
NoNO Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by NoNO Inc filed Critical NoNO Inc
Publication of CN102458441A publication Critical patent/CN102458441A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/162—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/10—Fusion polypeptide containing a localisation/targetting motif containing a tag for extracellular membrane crossing, e.g. TAT or VP22

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Virology (AREA)
  • Vascular Medicine (AREA)
  • Toxicology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Magnetic Resonance Imaging Apparatus (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Management, Administration, Business Operations System, And Electronic Commerce (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
CN2010800352462A 2009-06-10 2010-06-10 用于治疗神经疾病的模型系统和治疗方案 Pending CN102458441A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US18598909P 2009-06-10 2009-06-10
US61/185,989 2009-06-10
PCT/US2010/038200 WO2010144721A2 (en) 2009-06-10 2010-06-10 Model systems and treatment regimes for treatment of neurological disease

Publications (1)

Publication Number Publication Date
CN102458441A true CN102458441A (zh) 2012-05-16

Family

ID=43309469

Family Applications (1)

Application Number Title Priority Date Filing Date
CN2010800352462A Pending CN102458441A (zh) 2009-06-10 2010-06-10 用于治疗神经疾病的模型系统和治疗方案

Country Status (14)

Country Link
US (2) US8940699B2 (https=)
EP (2) EP2440230B1 (https=)
JP (2) JP6005514B2 (https=)
CN (1) CN102458441A (https=)
AU (1) AU2010258664B2 (https=)
BR (1) BRPI1010718A2 (https=)
CA (1) CA2765169C (https=)
DK (1) DK2440230T3 (https=)
ES (1) ES2847293T3 (https=)
HR (1) HRP20210112T1 (https=)
HU (1) HUE053131T2 (https=)
PL (1) PL2440230T3 (https=)
PT (1) PT2440230T (https=)
WO (1) WO2010144721A2 (https=)

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106661126A (zh) * 2014-05-28 2017-05-10 诺诺公司 TAT‑NR2B9c的氯盐
WO2018103038A1 (zh) * 2016-12-08 2018-06-14 拜西欧斯（北京）生物技术有限公司 一种缀合物及其应用
CN109106941A (zh) * 2012-11-28 2019-01-01 诺诺公司 Tat-nr2b9c的冻干制剂
WO2019006692A1 (zh) * 2017-07-05 2019-01-10 拜西欧斯（北京）生物技术有限公司 用于治疗、改善或预防神经系统相关病症的化合物及其用途
CN113735938A (zh) * 2021-07-30 2021-12-03 英纳氏(珠海)药业有限公司 一种神经保护多肽化合物及其应用
CN114469084A (zh) * 2022-04-02 2022-05-13 剑博微电子(深圳)有限公司 一种基于高精度adc的血氧监测系统
CN114642402A (zh) * 2022-03-07 2022-06-21 翰博瑞强(上海)医药科技有限公司 一种用于预测药物对心脏毒性影响的方法及心电图设备

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7510824B2 (en) * 1999-06-02 2009-03-31 Nono Inc. Method of screening peptides useful in treating traumatic injury to the brain or spinal cord
WO2010144721A2 (en) 2009-06-10 2010-12-16 Arbor Vita Corporation Model systems and treatment regimes for treatment of neurological disease
EP2616094B1 (en) 2010-08-12 2017-11-08 NoNO Inc. Treatment of penetrative injury to the brain
ES2912042T3 (es) 2011-06-24 2022-05-24 Nono Inc Terapia de combinación para isquemia
MX364562B (es) * 2011-12-13 2019-04-30 Nono Inc Terapia para hemorragia subaracnoidea e isquemia.
US9241970B2 (en) 2011-12-13 2016-01-26 Nono Inc. Therapy for subarachnoid hemorrhage and ischemia
AU2013204309A1 (en) * 2012-11-13 2014-05-29 Biodiem Limited Therapeutic Compounds and Uses Thereof
US10251935B2 (en) 2012-11-28 2019-04-09 Nono Inc. Lyophilized formulation comprising tat-NR2B9C, histidine and trehalose
KR102253900B1 (ko) * 2016-04-27 2021-05-18 바이오셀즈(베이징) 바이오테크 코., 엘티디. 흥분성 신경독성 관련 손상 치료용 펩타이드
EP3450446A1 (en) * 2016-04-27 2019-03-06 Biocells (Beijing) Biotech Co., Ltd. Treatment method for excitatory neurotoxicity-related injury
KR102403089B1 (ko) * 2017-07-05 2022-06-02 바이오셀즈(베이징) 바이오테크 코., 엘티디. 폴리펩타이드의 약학적으로 허용 가능한 염 및 이의 용도
KR102545825B1 (ko) 2017-09-30 2023-06-22 바이오셀즈(베이징) 바이오테크 코., 엘티디. 흥분성 신경 독성 관련 손상 치료를 위한 펩타이드 조성물
CN113121641B (zh) 2021-03-11 2022-11-01 武汉英纳氏药业有限公司 一类多功能多肽及其在医药领域的应用
CN113150065B (zh) 2021-03-11 2022-07-08 武汉英纳氏药业有限公司 一种合成肽及其应用

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060148711A1 (en) 1999-05-14 2006-07-06 Arbor Vita Corporation Molecular interactions in neurons
US7510824B2 (en) 1999-06-02 2009-03-31 Nono Inc. Method of screening peptides useful in treating traumatic injury to the brain or spinal cord
GB0025473D0 (en) 2000-10-17 2000-11-29 Pfizer Ltd Pharmaceutical combinations
WO2004045535A2 (en) * 2002-11-14 2004-06-03 Arbor Vita Corporation Molecular interactions in neurons
EP1601380A1 (en) 2003-02-13 2005-12-07 Licentia OY Use of a mast cell activation or degranulation blocking agent in the manufacture of a medicament for the treatment of cerebral ischemia
CA2524573A1 (en) 2003-05-02 2004-11-11 Paion Deutschland Gmbh Intravenous injection of non-neurotoxic plasminogen activators for the treatment of stroke
DK2043671T3 (da) * 2006-07-11 2020-06-15 Nono Inc Peptid og sammensætning deraf til anvendelse ved behandling af slagtilfælde med feber
EP1884521A1 (en) * 2006-07-31 2008-02-06 Xigen S.A. Fusion peptide for inhibiting interaction of neuronal NMDA receptor (NMDAR) and NMDAR interacting proteins
ES2446292T3 (es) * 2007-03-02 2014-03-07 Nono Inc. Tratamiento del accidente cerebrovascular y otras enfermedades sin inhibir los canales de calcio de tipo N
WO2009006611A1 (en) 2007-07-03 2009-01-08 Arbor Vita Corporation Small molecule inhibitors of pdz interactions
US8080518B2 (en) 2007-12-05 2011-12-20 Arbor Vita Corporation Co-administration of an agent linked to an internalization peptide with an anti-inflammatory
DK2320927T3 (en) 2008-07-09 2015-09-14 Univ Copenhagen Modified peptides as potent inhibitors of the PSD-95 / NMDA receptor interaction
WO2010144721A2 (en) 2009-06-10 2010-12-16 Arbor Vita Corporation Model systems and treatment regimes for treatment of neurological disease
ES2912042T3 (es) 2011-06-24 2022-05-24 Nono Inc Terapia de combinación para isquemia
US9241970B2 (en) 2011-12-13 2016-01-26 Nono Inc. Therapy for subarachnoid hemorrhage and ischemia
MX364562B (es) 2011-12-13 2019-04-30 Nono Inc Terapia para hemorragia subaracnoidea e isquemia.

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
CUI ,H.等: "PDZ protein interactions underlying NMDA receptor-mediated excitotoxicity and neuroprotection by PSD-95 inhibitors", 《J.NEUROSCI》 *
HONG-SHUO SUN等: "Effectiveness of PSD95 Inhibitors in Permanent and Transient Focal Ischemia in the Rat", 《STROKE》 *
MARTEL,M.A.等: "Inhibiting pro-death NMDA receptor signaling dependent on the NR2 PDZ ligand may not affect synaptic function or synaptic NMDA receptor signaling to gene expression", 《CHANNELS (AUSTIN)》 *

Cited By (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109106941A (zh) * 2012-11-28 2019-01-01 诺诺公司 Tat-nr2b9c的冻干制剂
CN106661126A (zh) * 2014-05-28 2017-05-10 诺诺公司 TAT‑NR2B9c的氯盐
CN106661126B (zh) * 2014-05-28 2021-12-10 诺诺公司 TAT-NR2B9c的氯盐
WO2018103038A1 (zh) * 2016-12-08 2018-06-14 拜西欧斯（北京）生物技术有限公司 一种缀合物及其应用
WO2019006692A1 (zh) * 2017-07-05 2019-01-10 拜西欧斯（北京）生物技术有限公司 用于治疗、改善或预防神经系统相关病症的化合物及其用途
CN113735938A (zh) * 2021-07-30 2021-12-03 英纳氏(珠海)药业有限公司 一种神经保护多肽化合物及其应用
CN113735938B (zh) * 2021-07-30 2024-11-08 英纳氏(珠海)药业有限公司 一种神经保护多肽化合物及其应用
CN114642402A (zh) * 2022-03-07 2022-06-21 翰博瑞强(上海)医药科技有限公司 一种用于预测药物对心脏毒性影响的方法及心电图设备
CN114469084A (zh) * 2022-04-02 2022-05-13 剑博微电子(深圳)有限公司 一种基于高精度adc的血氧监测系统

Also Published As

Publication number Publication date
AU2010258664B2 (en) 2015-05-28
BRPI1010718A2 (pt) 2016-03-15
HUE053131T2 (hu) 2021-06-28
EP2440230B1 (en) 2020-11-11
PL2440230T3 (pl) 2021-06-14
JP6005514B2 (ja) 2016-10-12
JP2012530057A (ja) 2012-11-29
JP6220371B2 (ja) 2017-10-25
US20120269733A1 (en) 2012-10-25
US8940699B2 (en) 2015-01-27
US20150202253A1 (en) 2015-07-23
JP2016041731A (ja) 2016-03-31
HRP20210112T1 (hr) 2021-04-16
AU2010258664A1 (en) 2012-01-12
CA2765169A1 (en) 2010-12-16
ES2847293T3 (es) 2021-08-02
PT2440230T (pt) 2021-02-03
US9610323B2 (en) 2017-04-04
WO2010144721A2 (en) 2010-12-16
EP2440230A2 (en) 2012-04-18
EP2440230A4 (en) 2014-05-28
EP3808366A1 (en) 2021-04-21
WO2010144721A3 (en) 2011-04-21
CA2765169C (en) 2019-06-18
DK2440230T3 (da) 2021-01-18

Similar Documents

Publication Publication Date Title
JP6220371B2 (ja) 神経疾患の治療のためのモデル系及び治療計画
US11878044B2 (en) Combination therapy for ischemia
JP6427104B2 (ja) Ｔａｔ−ＮＲ２Ｂ９ｃの凍結乾燥製剤
CN104053448B (zh) 一种蛛网膜下腔出血及局部缺血的治疗方法
US20240301003A1 (en) Plasmin-resistant peptides for improved therapeutic index
US10912817B2 (en) Prelyophilized, lyophilized and reconstituted formulations comprising TAT-NR2B9C with d-amino acids, histidine and trehalose
US20230055441A1 (en) Plasmin-resistant peptides for treating stroke and related conditions
US20230285504A1 (en) Inhibition of reperfusion injury with a psd-95 inhibitor
HK40050639A (en) Treatment regimes for treatment of neurological disease
HK40096295A (zh) 用於提高治疗指数的抗纤溶酶肽
HK1215793B (en) Lyophilized formulation of tat-nr2b9c

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
RJ01 Rejection of invention patent application after publication

Application publication date: 20120516

RJ01 Rejection of invention patent application after publication